A systematic review of Phase 2 and 3 clinical trials published between 2021 and 2026 maps the emerging landscape of obesity pharmacotherapy. GLP-1 monotherapy achieves roughly 10–15% weight loss, while dual agonists tirzepatide and CagriSema and the amylin-GLP-1 fusion amycretin surpass 20%. The triple agonist retatrutide—simultaneously targeting GLP-1, GIP, and glucagon receptors—exceeds 25% weight reduction. Critically, benefits extend to cardiovascular event reduction, heart failure symptom improvement, obstructive sleep apnea severity, MASH resolution, slowed CKD progression, and osteoarthritis pain relief.
The therapeutic arc here is paradigm-shifting, not merely incremental. For the first time, obesity pharmacotherapy is producing outcomes that rival or challenge bariatric surgery benchmarks—historically the only intervention achieving sustained 25%+ weight reduction with systemic metabolic benefits. The multi-receptor approach reflects a maturing understanding that obesity is a neuroendocrine disease, not simply caloric imbalance, and that targeting complementary gut-hormone pathways produces synergistic effects on appetite circuits and metabolic homeostasis.
Important caveats apply: this is a review synthesizing trials rather than original data, so effect sizes reflect best-case controlled-trial populations. Long-term safety data for newer agents like retatrutide remain immature. Access inequities, cost burdens, and medication discontinuation rates—which can lead to rapid weight regain—represent underexplored real-world limitations. For practicing clinicians and health-conscious adults, the clinical signal is clear: phenotype-guided, complication-targeted prescribing is emerging as the new standard of care.